幸运8平台彩票

PerkinElmer
014624_1920x400.jpg

Application Brief

Robust Atorvastatin Analysis Under High Aqueous LC Conditions Application Brief

Introduction

The origin of statins dates back to the mid 1970’s when the Japanese biochemist, Akira Endo, isolated a factor from the fungus Penicillium citrinum which he identified as a competitive inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMG-CoA reductase). This substance, which he named compactin or mevastatin, was the first statin to be administered to humans. Statins competitively inhibit HMG-CoA reductase, an enzyme involved in cholesterol synthesis, especially in the liver. Used to prevent cardiovascular disease and to lower cholesterol levels, atorvastatin is one of a number of synthetic statins routinely produced. It is now the most commonly prescribed statin medication. This application brief describes the robust HPLC analysis of the polar compound atorvastatin using a gradient which reaches 100% aqueous mobile phase conditions.